Orion Oyj
12.1.2026 14:00:00 CET | Globenewswire | Press release
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
12 January 2026 at 15:00 EET
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 9 January 2026 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 4.97% shares Below 5% voting rights | 0.04% shares Below 5% voting rights | 5.01% shares Below 5% voting rights | 141,134,278 shares 744,770,339 voting rights |
| Position of previous notification (if applicable) | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 7,014,577 shares Below 5% voting rights | 4.97% shares Below 5% voting rights | ||
| POINT A SUBTOTAL | 7,014,577 shares Below 5% voting rights | 4.97% shares Below 5% voting rights | ||
Point B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| American Depositary Receipt (US68628Y1047) | N/A | N/A | Physical | 200 shares Below 5% voting rights | 0.00% shares Below 5% voting rights |
| Securities Lent | N/A | N/A | Physical | 56,980 shares Below 5% voting rights | 0.04% shares Below 5% voting rights |
| POINT B SUBTOTAL | 57,180 shares Below 5% voting rights | 0.04% shares Below 5% voting rights |
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ISS A/S11.8.2026 07:24:31 CEST | Press release
ISS commences the second tranche of its share buyback programme including the announced increase by DKK 600 million
ISS A/S11.8.2026 07:23:51 CEST | Press release
Interim Report for 1 January – 30 June 2026
Idorsia Pharmaceuticals Ltd11.8.2026 07:00:00 CEST | Press release
Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
Tecan Group AG11.8.2026 07:00:00 CEST | Press release
Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed
Trifork Group AG11.8.2026 07:00:00 CEST | Press release
Trifork subsidiary Nine to maintain and further develop Denmark’s digital admissions platform for higher education
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom